Qiagen (NYSE:QGEN) Updates FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.500- for the period, compared to the consensus EPS estimate of 2.630. The company issued revenue guidance of $2.2 billion-, compared to the consensus revenue estimate of $2.2 billion. Qiagen also updated its Q1 2026 guidance to 0.540- EPS.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on QGEN shares. Wall Street Zen downgraded shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Barclays set a $58.00 price target on Qiagen and gave the stock an “overweight” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft downgraded shares of Qiagen from a “buy” rating to a “hold” rating and raised their price target for the company from $52.00 to $54.00 in a report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $50.00 target price on Qiagen and gave the stock a “hold” rating in a report on Friday. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Qiagen has a consensus rating of “Hold” and an average target price of $54.68.

Qiagen Stock Performance

QGEN stock traded up $0.08 during midday trading on Friday, hitting $51.31. The stock had a trading volume of 1,511,822 shares, compared to its average volume of 3,130,321. The company has a current ratio of 2.60, a quick ratio of 2.30 and a debt-to-equity ratio of 0.45. The stock has a 50-day simple moving average of $49.63 and a 200 day simple moving average of $49.67. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81. The firm has a market capitalization of $10.84 billion, a price-to-earnings ratio of 25.45, a P/E/G ratio of 2.48 and a beta of 0.67.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.82%. The firm had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. During the same quarter last year, the company earned $0.61 earnings per share. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, equities research analysts anticipate that Qiagen will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently bought and sold shares of QGEN. Global Retirement Partners LLC grew its holdings in Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after acquiring an additional 851 shares during the last quarter. Danske Bank A S bought a new position in Qiagen during the 3rd quarter worth approximately $36,000. Advisory Services Network LLC bought a new position in shares of Qiagen during the third quarter worth $64,000. Dark Forest Capital Management LP bought a new position in Qiagen during the third quarter worth about $283,000. Finally, XTX Topco Ltd bought a new position in shares of Qiagen during the 3rd quarter valued at about $749,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.